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Background: The chromosomal translocation BCR-ABL1 is frequently present in adult B cell precursor 
acute lymphoblastic leukemia (BCP-ALL) in about 30% of the patients, while in pediatric BCP-ALL 
it occurs only in 3% of the patients. However, in both cases the disease is characterized by the almost 
obligatory presence of IKZF1 gene deletions and mutations, arguing that loss of IKZF1 function is 
required for oncogenic transformation by p190
BCR-ABL1
. The IKZF1 gene encodes the transcription 
factor IKZF1 (Ikaros), which mainly acts as a transcriptional repressor protein through the recruitment 
of both HDAC-dependent and HDAC-independent co-repressor molecules. However, in some cases 
IKZF1 has also been shown to transcriptional activate specific target genes through association with 
the SWI/SNF chromatin remodeling complexes. We hypothesized that IKZF1-mediated transcription 
in a direct or indirect manner is modulated by BCR-ABL1 signaling. Therefore, cell biological assays 
and proteomic studies were performed to investigate the effect of p190
BCR-ABL1
 expression on IKZF1 
protein function. 
Results: Using a luciferase reporter assay employing the human Bax- promoter, we establsihed that 
IKZF1-induced transcriptional repression was alleviated by p190
BCR-ABL1
 expression. This effect could 
be reversed by Imatinib treatment, suggesting that BCR-ABL1 signaling interferes with the normal 
function of IKZF1. Next, we assessed the effect of p190
BCR-ABL1
 on doxycycline-induced expression of 
IKZF1 using the murine lymphoid Tet-on Ba/F3 (TonB) cell line. Gene expression analysis showed 
that several target genes that are repressed by IKZF1 in TonB cells, such as p16Ink4a, Cnot6, Dscc1 
and Tspan5, are transcriptionally induced by co-expression of p190
BCR-ABL1
. In order to understand 
how p190
BCR-ABL1
 signaling affects IKZF1 protein function, mass spectrometry was performed on 
FLAG-affinity purified IKZF1 from transiently transfected HEK293 cells in the absence or presence 
of p190
BCR-ABL1
. These analyses revealed that p190
BCR-ABL1
 expression induces phosphorylation of 
IKZF1 on specific serine, threonine and tyrosine residues as well lysine acetylation. Transient 
transfection of lysine acetyltransferase PCAF (KAT2B) confirmed that IKZF1 is modified by lysine 
acetylation.  Western blot analysis using phospho-specific antibodies showed that IKZF1 is subject to 
tyrosine phosphorylation by p190
BCR-ABL1
, both in HEK293 cells and TonB cells.  Using an in vitro 
kinase assay, we demonstrated that IKZF1 can be directly phosphorylated by active recombinant ABL 
kinase.  
Conclusion: Our studies show that p190
BCR-ABL1
 signaling induces a multitude of different post-
translational modifications on IKZF1, which could modify its properties as transcriptional regulator. 
We hypothesize that modulation of IKZF1 tumor suppressor function by p190
BCR-ABL1
 signaling is the 
driving force for IKZF1 gene deletions in BCP-ALL patients harboring a BCR-ABL1 translocation.        
 
